Erectile Dysfunction Drugs Market By Products (Sildenafil, Tadalafil, Udenafil, Avanafil , Others), By Mode of Administration  (Oral Medication , Injectable Medication ), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

Erectile Dysfunction Drugs Market

Erectile dysfunction (ED) drugs are the medications used to treat erectile dysfunction, a condition where a man is unable to achieve or maintain an erection sufficient for sexual intercourse. These drugs work by increasing blood flow to the penis, which helps to produce and maintain an erection. These drugs are available by prescription only, and should only be used under the guidance of a healthcare provider.  The three most commonly prescribed erectile dysfunction drugs are sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). These drugs are generally safe and effective, however, they can have side effects, including headache, facial flushing, nasal congestion, and indigestion. 

Key factors driving the growth of the erectile dysfunction drugs market include increasing prevalence of erectile dysfunction, growing awareness about erectile dysfunction, and advancements in drug development. The prevalence of ED has been increasing over the years, majorly due to the growing incidence of chronic diseases such as diabetes and cardiovascular disease. These conditions can damage blood vessels and nerves, making it more difficult for men to achieve and maintain an erection. For instance, according to the World Health Organization in 2020, it was estimated that more than 300 million men worldwide suffer from some form of erectile dysfunction, and is expected to rise to over 322 million by 2025. 

Furthermore, the rise in awareness about erectile dysfunction among the general population has led to an increased demand for treatment options, which, in turn, drives the growth of the market. In addition, increase in media coverage of ED, with more articles and television programs discussing the condition and its impact on men's health. This has helped to raise awareness among the general population and reduce the stigma associated with seeking treatment for ED.  Moreover, advancements in drug development for erectile dysfunction, with newer and more effective drugs further contribute to the market growth. For instance, in 2020 Teva Pharmaceutical Industries Ltd. had launched ALYQ, a generic version of ADCIRCA1 (tadalafil) tablets, 20 mg in the U.S. for erectile dysfunction. 

Increased availability of over-the-counter drugs, and high growth potential in developing economies are expected to create lucrative growth opportunities for the erectile dysfunction drugs market. Several erectile dysfunction drugs have been approved for OTC sale in certain countries, including sildenafil (Viagra) in the UK and Australia, and avanafil (Spedra) in some European countries. The availability of OTC erectile dysfunction drugs can help to reduce healthcare costs, as it can decrease the need for expensive doctor's visits and prescription medications. Thus, the availability of OTC erectile dysfunction drugs is expected to create lucrative opportunities for the growth of the erectile dysfunction drugs market. 

Moreover, erectile dysfunction drugs market is expected to experience significant growth, particularly in developing economies. This is attributed to an increase in the prevalence of lifestyle and chronic diseases, such as diabetes, hypertension, and obesity, which are known to contribute to the development of erectile dysfunction. The rise in the aging population in these regions is also expected to create lucrative opportunities for market growth. In addition, the availability of generic drugs, along with the growing awareness about health and the availability of advanced treatments for erectile dysfunction, is expected to further drive the growth of the market. 

The erectile dysfunction drugs market is segmented on the basis of product, mode of administration, distribution channel, and region. On the basis of product, the market is classified into sildenafil, avanafil, tadalafil, udenafil, and others. On the basis of the mode of administration, the market is bifurcated into oral and injectable medications. On the basis of distribution channels, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

The key players profiled in the study of erectile dysfunction drugs market include Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed Pharma, Glenmark Pharmaceuticals Limited, and Cipla Ltd. 

Key Market Insights  

By product, the sildenafil segment was the highest revenue contributor to the market in 2022 and is estimated to reach $2,959.59 million by 2032. 

By mode of administration, the oral medication segment dominated the global market in 2022.  

By distribution channel, the hospital pharmacy segment was the highest revenue contributor to the market in 2022. 

Based on region, North America garnered the largest revenue share in 2022. However, Asia-Pacific is the fastest growing segment during the forecast period with CAGR of 7.5% 

Overview

The erectile dysfunction drugs market was valued at $2.6 billion in 2022 and is projected to reach $5.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032. Erectile dysfunction (ED) is a common sexual health condition that affects men of all ages. It is defined as the inability to get or maintain an erection sufficient for sexual intercourse. Erectile dysfunction (ED) is often caused by underlying medical conditions such as high blood pressure, diabetes, or heart problems. Other factors that may contribute to erectile dysfunction (ED) include stress, anxiety, depression, nerve damage, certain medications, and lifestyle factors such as smoking and drinking alcohol. Treatment options for erectile dysfunction (ED) include medications, lifestyle changes, and psychological counseling.  

The key factor that drives the growth of the erectile dysfunction drugs market are, the increase in the prevalence of chronic disease such as diabetes, hypertension, obesity, and others, and rise in awareness about benefits associated with erectile dysfunction treatment in developing countries such as India and China boost the growth of the market. In addition, the rise in adoption of sedentary lifestyle and surge in the number of erectile dysfunction cases across the globe further boosts the growth of the market. For instance, according to the National Institutes of Health, in 2022, erectile dysfunction (ED) is common condition in the U.S. It affects about 30 million men in the U.S. every year.  

However, side effects associated with erectile dysfunction drugs such as blurred vision, nasal congestion, and flushing; and lack of awareness and knowledge about erectile dysfunction among the general population are anticipated to hamper the market growth in the upcoming years. On the contrary, increase in R&D activities in erectile dysfunction treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.  

The erectile dysfunction drugs market is segmented on the basis of product, mode of administration, distribution channel and region. On the basis of product, the market is classified into sildenafil , Avanfil, Tadalafil, udenafil, and others. On the basis of mode of administration, the market is bifurcated into oral medications and injectable medication. On the basis of distribution channel, the market is classified into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).  

Major players profiled in the report are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed Pharma, Glenmark Pharmaceuticals Limited, and Cipla Ltd. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the erectile dysfunction drugs market analysis from 2022 to 2032 to identify the prevailing erectile dysfunction drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the erectile dysfunction drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global erectile dysfunction drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Vivus LLC

Scope of Erectile Dysfunction Drugs Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of erectile dysfunction

3.4.1.2. Rise in the prevalence of psychological disorders

3.4.2. Restraints

3.4.2.1. Side effects associated with erectile dysfunction drugs

3.4.3. Opportunities

3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Sildenafil

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Tadalafil

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Udenafil

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Avanafil

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Others

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral Medication

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Injectable Medication

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacy

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Retail Pharmacy

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Pharmacy

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Products

7.2.3. Market size and forecast, by Mode of Administration

7.2.4. Market size and forecast, by Distribution Channels

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Products

7.2.5.1.3. Market size and forecast, by Mode of Administration

7.2.5.1.4. Market size and forecast, by Distribution Channels

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Products

7.2.5.2.3. Market size and forecast, by Mode of Administration

7.2.5.2.4. Market size and forecast, by Distribution Channels

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Products

7.2.5.3.3. Market size and forecast, by Mode of Administration

7.2.5.3.4. Market size and forecast, by Distribution Channels

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Products

7.3.3. Market size and forecast, by Mode of Administration

7.3.4. Market size and forecast, by Distribution Channels

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Products

7.3.5.1.3. Market size and forecast, by Mode of Administration

7.3.5.1.4. Market size and forecast, by Distribution Channels

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Products

7.3.5.2.3. Market size and forecast, by Mode of Administration

7.3.5.2.4. Market size and forecast, by Distribution Channels

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Products

7.3.5.3.3. Market size and forecast, by Mode of Administration

7.3.5.3.4. Market size and forecast, by Distribution Channels

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Products

7.3.5.4.3. Market size and forecast, by Mode of Administration

7.3.5.4.4. Market size and forecast, by Distribution Channels

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Products

7.3.5.5.3. Market size and forecast, by Mode of Administration

7.3.5.5.4. Market size and forecast, by Distribution Channels

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Products

7.3.5.6.3. Market size and forecast, by Mode of Administration

7.3.5.6.4. Market size and forecast, by Distribution Channels

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Products

7.4.3. Market size and forecast, by Mode of Administration

7.4.4. Market size and forecast, by Distribution Channels

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Products

7.4.5.1.3. Market size and forecast, by Mode of Administration

7.4.5.1.4. Market size and forecast, by Distribution Channels

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Products

7.4.5.2.3. Market size and forecast, by Mode of Administration

7.4.5.2.4. Market size and forecast, by Distribution Channels

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Products

7.4.5.3.3. Market size and forecast, by Mode of Administration

7.4.5.3.4. Market size and forecast, by Distribution Channels

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Products

7.4.5.4.3. Market size and forecast, by Mode of Administration

7.4.5.4.4. Market size and forecast, by Distribution Channels

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Products

7.4.5.5.3. Market size and forecast, by Mode of Administration

7.4.5.5.4. Market size and forecast, by Distribution Channels

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Products

7.4.5.6.3. Market size and forecast, by Mode of Administration

7.4.5.6.4. Market size and forecast, by Distribution Channels

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Products

7.5.3. Market size and forecast, by Mode of Administration

7.5.4. Market size and forecast, by Distribution Channels

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Products

7.5.5.1.3. Market size and forecast, by Mode of Administration

7.5.5.1.4. Market size and forecast, by Distribution Channels

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Products

7.5.5.2.3. Market size and forecast, by Mode of Administration

7.5.5.2.4. Market size and forecast, by Distribution Channels

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Products

7.5.5.3.3. Market size and forecast, by Mode of Administration

7.5.5.3.4. Market size and forecast, by Distribution Channels

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Products

7.5.5.4.3. Market size and forecast, by Mode of Administration

7.5.5.4.4. Market size and forecast, by Distribution Channels

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Pfizer Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Eli Lilly and Company

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Teva Pharmaceutical Industries Ltd.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. Sanofi

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Bayer AG

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Vivus LLC.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.7. Adamed

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.8. Glenmark Pharmaceuticals Limited

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.8.7. Key strategic moves and developments

9.9. Cipla Ltd

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Sun Pharmaceutical Industries Limited

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 02. ERECTILE DYSFUNCTION DRUGS MARKET FOR SILDENAFIL, BY REGION, 2022-2032 ($MILLION)

TABLE 03. ERECTILE DYSFUNCTION DRUGS MARKET FOR TADALAFIL, BY REGION, 2022-2032 ($MILLION)

TABLE 04. ERECTILE DYSFUNCTION DRUGS MARKET FOR UDENAFIL, BY REGION, 2022-2032 ($MILLION)

TABLE 05. ERECTILE DYSFUNCTION DRUGS MARKET FOR AVANAFIL , BY REGION, 2022-2032 ($MILLION)

TABLE 06. ERECTILE DYSFUNCTION DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 07. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 08. ERECTILE DYSFUNCTION DRUGS MARKET FOR ORAL MEDICATION , BY REGION, 2022-2032 ($MILLION)

TABLE 09. ERECTILE DYSFUNCTION DRUGS MARKET FOR INJECTABLE MEDICATION , BY REGION, 2022-2032 ($MILLION)

TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 11. ERECTILE DYSFUNCTION DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)

TABLE 12. ERECTILE DYSFUNCTION DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)

TABLE 13. ERECTILE DYSFUNCTION DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)

TABLE 14. ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 18. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 19. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 20. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 21. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 22. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 23. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 24. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 25. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 26. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 27. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 28. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 29. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 30. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 31. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 32. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 33. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 34. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 35. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 36. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 37. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 38. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 39. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 40. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 41. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 42. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 43. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 44. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 45. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 46. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 49. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 53. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 54. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 55. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 56. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 57. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 58. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 59. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 60. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 61. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 62. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 63. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 64. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 65. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 68. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 72. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 73. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 74. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 75. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 76. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 77. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 78. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 81. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 84. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)

TABLE 87. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)

TABLE 88. PFIZER INC.: KEY EXECUTIVES

TABLE 89. PFIZER INC.: COMPANY SNAPSHOT

TABLE 90. PFIZER INC.: PRODUCT SEGMENTS

TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 92. PFIZER INC.: KEY STRATERGIES

TABLE 93. ELI LILLY AND COMPANY: KEY EXECUTIVES

TABLE 94. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 95. ELI LILLY AND COMPANY: PRODUCT SEGMENTS

TABLE 96. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES

TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS

TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 101. SANOFI: KEY EXECUTIVES

TABLE 102. SANOFI: COMPANY SNAPSHOT

TABLE 103. SANOFI: PRODUCT SEGMENTS

TABLE 104. SANOFI: PRODUCT PORTFOLIO

TABLE 105. BAYER AG: KEY EXECUTIVES

TABLE 106. BAYER AG: COMPANY SNAPSHOT

TABLE 107. BAYER AG: PRODUCT SEGMENTS

TABLE 108. BAYER AG: PRODUCT PORTFOLIO

TABLE 109. VIVUS LLC.: KEY EXECUTIVES

TABLE 110. VIVUS LLC.: COMPANY SNAPSHOT

TABLE 111. VIVUS LLC.: PRODUCT SEGMENTS

TABLE 112. VIVUS LLC.: SERVICE SEGMENTS

TABLE 113. VIVUS LLC.: PRODUCT PORTFOLIO

TABLE 114. ADAMED: KEY EXECUTIVES

TABLE 115. ADAMED: COMPANY SNAPSHOT

TABLE 116. ADAMED: PRODUCT SEGMENTS

TABLE 117. ADAMED: PRODUCT PORTFOLIO

TABLE 118. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES

TABLE 119. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT

TABLE 120. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS

TABLE 121. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

TABLE 122. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES

TABLE 123. CIPLA LTD: KEY EXECUTIVES

TABLE 124. CIPLA LTD: COMPANY SNAPSHOT

TABLE 125. CIPLA LTD: PRODUCT SEGMENTS

TABLE 126. CIPLA LTD: PRODUCT PORTFOLIO

TABLE 127. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN ERECTILE DYSFUNCTION DRUGS MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALERECTILE DYSFUNCTION DRUGS MARKET

FIGURE 10. ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR SILDENAFIL, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR TADALAFIL, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR UDENAFIL, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR AVANAFIL , BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR ORAL MEDICATION , BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR INJECTABLE MEDICATION , BY COUNTRY 2022 AND 2032(%)

FIGURE 19. ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. ERECTILE DYSFUNCTION DRUGS MARKET BY REGION, 2022

FIGURE 24. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 25. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 26. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 27. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 28. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 29. UK ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 30. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 31. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 32. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 33. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 34. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 35. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 36. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 37. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 38. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 39. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 40. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 41. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 42. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47. COMPETITIVE DASHBOARD

FIGURE 48. COMPETITIVE HEATMAP: ERECTILE DYSFUNCTION DRUGS MARKET

FIGURE 49. TOP PLAYER POSITIONING, 2022

FIGURE 50. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 51. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 52. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 53. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 54. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 56. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. SANOFI: NET SALES, 2020-2022 ($MILLION)

FIGURE 58. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. SANOFI: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 61. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2020-2022 ($MILLION)

FIGURE 64. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 65. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 66. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%